A composition is provided including a compound (A) represented by Formula (1) and a compound (B) represented by Formula (2), wherein the compound (B) is contained in an amount of 0.00002 to 0.2 parts by mass with respect to 100 parts by mass of the compound (A): (R.sub.1—COO).sub.n—R.sub.2—(NCO).sub.m . . . (1) (in Formula (1), R.sub.1 is an ethylenically unsaturated group having 2 to 7 carbon atoms; R.sub.2 is an (m+n)-valent hydrocarbon group having 1 to 7 carbon atoms; and n and m are each an integer of 1 or 2) ##STR00001##
(in Formula (2), R is (—R.sub.2—(OCO—R.sub.1), and R.sub.1 and R.sub.2 are the same as those in Formula (1)).

A composition is provided including a compound (A) represented by Formula (1) and a compound (B) represented by Formula (2), wherein the compound (B) is contained in an amount of 0.00002 to 0.2 parts by mass with respect to 100 parts by mass of the compound (A): (R.sub.1—COO).sub.n—R.sub.2—(NCO).sub.m . . . (1) (in Formula (1), R.sub.1 is an ethylenically unsaturated group having 2 to 7 carbon atoms; R.sub.2 is an (m+n)-valent hydrocarbon group having 1 to 7 carbon atoms; and n and m are each an integer of 1 or 2) ##STR00001##
(in Formula (2), R is (—R.sub.2—(OCO—R.sub.1), and R.sub.1 and R.sub.2 are the same as those in Formula (1)).

In one embodiment, the present application discloses a photo-cleavable surface binding compound of the Formula I and Formula II:

##STR00001##

wherein the variables EG, EG1, SP1, SP2, SP3, Ar and BG are as defined herein. In another embodiment, the application discloses a method for forming a coating on a surface of a substrate using the surface binding compound.

In one embodiment, the present application discloses a photo-cleavable surface binding compound of the Formula I and Formula II:

##STR00001##

wherein the variables EG, EG1, SP1, SP2, SP3, Ar and BG are as defined herein. In another embodiment, the application discloses a method for forming a coating on a surface of a substrate using the surface binding compound.

The present invention provides: a 3-alkoxybenzamide derivative having an excellent pest control effect, or a salt thereof; and a pest control agent and a production intermediate which contain the same as an active ingredient.

Provided are: a 3-alkoxybenzamide derivative represented by general formula [I]

##STR00001##

[In the formula, A represents an oxygen atom or a sulfur atom, G represents a hydrogen atom, a halogen atom, or a C.sub.1-C.sub.6 alkyl group, le represents a C.sub.1-C.sub.6 alkyl group, a C.sub.3-C.sub.6 cycloalkyl group, etc., R.sup.2 represents a hydrogen atom, etc., R.sup.3 represents a halogen atom, C.sub.1-C.sub.6 alkyl group, etc., R.sup.4 represents a halogen atom, C.sub.1-C.sub.6 alkyl group, etc., and R.sup.5 represents a C.sub.1-C.sub.12 alkyl group, etc.], or a salt thereof; and a pest control agent characterized by containing said derivative or salt thereof as an active ingredient.

A preparation method for salicylamine acetate, comprising preparing an amino-protected intermediate from salicylaldehyde, and reacting the intermediate with acetic acid to prepare an acetate.

A preparation method for salicylamine acetate, comprising preparing an amino-protected intermediate from salicylaldehyde, and reacting the intermediate with acetic acid to prepare an acetate.

Certain embodiments of the invention provide lipids useful for preparing lipid nanoparticles for delivering therapeutic agents to, e.g., hepatic stellate cells.

Certain embodiments of the invention provide lipids useful for preparing lipid nanoparticles for delivering therapeutic agents to, e.g., hepatic stellate cells.

One aspect of the invention provides a composition of novel high penetration compositions (HPC) or a high penetration prodrug (HPP) for treatment of Parkinson's disease. The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.